---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-001895"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:57:01.879389+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics reports FY2024 revenue up 9% to $15M; operating loss narrows 35%

## Summary
- Revenue $15.0M (+9% YoY); product revenue increased 26%; gross profit $9.0M at 60% margin.
- Operating loss reduced 35% to $11.2M from $17.3M; operating expenses down 21%.
- Cash $6.3M; raised $17.9M via four equity transactions including $7.5M from New Seneca Partners.
- FDA 510(k) clearance for DNA appliance to treat moderate-to-severe OSA in children ages 6-17.
- New strategic alliance with Rebis Health; expects 4-6x increase in revenue per case under new distribution model.

## SEC filing metadata
- accession: 0001641172-25-001895
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000164117225001895/0001641172-25-001895-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000164117225001895/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-001895
- JSON: https://secwatch.observer/filing/0001641172-25-001895.json
- Plain text: https://secwatch.observer/filing/0001641172-25-001895.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.